1. Metastatic Renal Cell Carcinoma

2. Program Goals

3. Incidence of RCC in the United States

4. Survival

5. Current Treatment

6. Toxicities to Treatment

7. IL-2: Function

8. Challenges in Clinical Outcome With Targeted Drugs

9. Nivolumab Mechanism of Action

10. Nivolumab Monotherapy Phase 2 Study Design

11. Prior Therapy in Metastatic Setting

12. PFS Doses of Nivolumab

13. Objective Responses With Nivolumab

14. Duration of Response By Nivolumab Dose (Responding Patients)

15. Nivolumab Monotherapy Treatment-Related AEs

16. Overall Survival

17. Response According to PD-L1 Status by IHC

18. Nivolumab + Sunitinib or Pazopanib

19. Baseline Patient Characteristics

20. Antitumor Activity (per RECIST 1.1)

21. Grade 3-4 Treatment-Related AEs in ≥ 10% of Patients

22. Nivolumab plus Ipilimumab Mechanism of Action

23. CA209-016 (NCT01472081): Phase I Study Design (N + I cohort)

24. Nivolumab + Ipilimumab Dosing schedule

25. Nivolumab + Ipilimumab Baseline Patient Characteristics

26. MPDL3280A Phase 1a Baseline Demographics RCC Patients in Dose-escalation and Dose-expansion Cohorts

27. Nivolumab + Ipilimumab Antitumor Activity

28. Nivolumab + Ipilimumab Time to Response and DOR

29. Nivolumab + Ipilimumab Treatment-Related AEs

30. Nivolumab Next Steps

32. MPDL3280A Phase 1a Safety Overview (RCC)

33. MPDL3280A Phase 1a Efficacy Summary Investigator Assessed

34. Other Checkpoint Inhibitor Trials to Watch

35. Conclusions

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)

39. References

40. References (cont)

41. References (cont)

42. References (cont)

43. References (cont)

44. References (cont)

45. References (cont)

46. References (cont)

47. References (cont)

48. References (cont)

49. References (cont)

50. References (cont)

51. References (cont)